News

Roche: Forget Tariffs And Focus On The Positives - There Are Many
Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...
The Pharma Letter6d
Roche-Zealand alliance could shake up obesity market
The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's (NOV: N) Wegovy (semaglutide) ...
Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche
The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed ...
BioSpace3d
Viking Rises as Pfizer’s Oral Obesity Med Falters
Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.
pharmaphorum2d
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...